Episode
Parkinson’s in the Clinic, Insilico enters Phase III, Vertex Acquires Crinetics
- Podcast
- Touching Base
- Published
- Jul 17, 2026
- Duration seconds
- 1942
- Processing state
not_requested- Canonical source
- https://shows.acast.com/touching-base/episodes/parkinsons-in-the-clinic-insilico-enters-phase-iii-vertex-ac
Actions
POST https://stenobird.com/v1/public/podcasts/touching-base-6714887/episodes/parkinson-s-in-the-clinic-insilico-enters-phase-iii-vertex-acquires-crinetics/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/touching-base-6714887/parkinson-s-in-the-clinic-insilico-enters-phase-iii-vertex-acquires-crinetics.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Promise hits Parkinson’s disease therapy, as a Phase I/II clinical study has demonstrated the feasibility of transplanting stem-cell-derived dopamine progenitor cells into the brain. In preclinical research, a new platform uses the brain’s fluid transport pathways to effectively deliver AAVs to therapeutic targets in mice. We’ll also cover the accelerating infrastructure moment for AI-driven drug discovery, with billion-dollar investments flowing into end-to-end platforms driven by models and compute, rather than single drug assets. In business, Insilico’s revenue leaps as the company’s AI-developed lead candidate moves to Phase III, while Vertex acquires Crinetics for $10 billion. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base : Engineered AAVs Harness Glymphatic System to Reach Brain Targets in Mice GEN , July 9, 2026 Stem Cell Therapy Shows Promise in First Human Parkinson’s Disease Trial GEN , July 9, 2026 Pharma Races to Scale AI as Billions Flow into Drug Discovery By Fay Lin, PhD, GEN Edge , July 6, 2026 StockWatch: Insilico Projects Profit, Revenue Leaps as AI-Developed Lead Candidate Moves to Phase III By Alex Philippidis, GEN Edge , July 12, 2026 Vertex Eyes Expansion Beyond Cystic Fibrosis with Planned $10B Crinetics Buyout By Alex Philippidis, GEN Edge , July 7, 2026 Top 20 Drugs Heading for the Patent Cliff, 2026-2029 By Alex Philippidis, GEN Magazine , Nov 1, 2025 Touching Base Podcast Hosted…